Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.

BMC cancer - 30 Mar 2020

Sriskandarajah Priya, De Haven Brandon Alexis, MacLeod Kenneth, Carragher Neil O, Kirkin Vladimir, Kaiser Martin, Whittaker Steven R

Abstract excerpt

BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxicities and the development of resistance. Dexamethasone (Dex) is a corticosteroid commonly used in clinical practice,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dexamethasone
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Multiple Myeloma

Share to Pyridones

Share to Pyrimidinones

Share to Pyruvate Dehydrogenase Acetyl-Transferring Kinase

Share to Receptors, Glucocorticoid

Source

Open in PubMed Open full text

Identifiers

PMID: 32228485
DOI: 10.1186/s12885-020-06735-2
PMCID: PMC7106683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.PMID 32228485Read ↗

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read ↗

Crosstalk between the glucocorticoid and mineralocorticoid receptor boosts glucocorticoid-induced killing of multiple myeloma cellsSemantic proximity Read ↗

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read ↗

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.Semantic proximity Read ↗

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read ↗

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read ↗

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read ↗

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSemantic proximity Read ↗

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.Semantic proximity Read ↗

Novel combination approaches for myeloma.Semantic proximity Read ↗

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.Semantic proximity Read ↗

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.